You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
A Phase I, Open-Label, Multicenter, Dose-escalation Study of the Oral Selective FGFR Inhibitor Debio 1347 in Patients with Advanced Solid Tumors Harboring FGFR Gene Alterations
|
|---|---|
| Published in |
Clinical Cancer Research, May 2019
|
| DOI | 10.1158/1078-0432.ccr-18-1959 |
| Pubmed ID | |
| Authors |
Martin H. Voss, Cinta Hierro, Rebecca S. Heist, James M. Cleary, Funda Meric-Bernstam, Josep Tabernero, Filip Janku, Leena Gandhi, A. John Iafrate, Darrell R. Borger, Nobuya Ishii, Youyou Hu, Yulia Kirpicheva, Valerie Nicolas-Metral, Anna Pokorska-Bocci, Anne Vaslin Chessex, Claudio Zanna, Keith T. Flaherty, Jose Baselga |
X Demographics
The data shown below were collected from the profiles of 18 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 6 | 33% |
| Japan | 2 | 11% |
| Colombia | 1 | 6% |
| Spain | 1 | 6% |
| Unknown | 8 | 44% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 10 | 56% |
| Practitioners (doctors, other healthcare professionals) | 5 | 28% |
| Scientists | 2 | 11% |
| Unknown | 1 | 6% |
Mendeley readers
The data shown below were compiled from readership statistics for 92 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 92 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 12 | 13% |
| Student > Master | 7 | 8% |
| Student > Doctoral Student | 6 | 7% |
| Student > Bachelor | 5 | 5% |
| Other | 5 | 5% |
| Other | 18 | 20% |
| Unknown | 39 | 42% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 19 | 21% |
| Biochemistry, Genetics and Molecular Biology | 9 | 10% |
| Nursing and Health Professions | 6 | 7% |
| Pharmacology, Toxicology and Pharmaceutical Science | 4 | 4% |
| Computer Science | 3 | 3% |
| Other | 6 | 7% |
| Unknown | 45 | 49% |
Attention Score in Context
This research output has an Altmetric Attention Score of 18. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 22 April 2021.
All research outputs
#1,958,153
of 24,998,746 outputs
Outputs from Clinical Cancer Research
#1,529
of 13,160 outputs
Outputs of similar age
#42,206
of 356,364 outputs
Outputs of similar age from Clinical Cancer Research
#33
of 190 outputs
Altmetric has tracked 24,998,746 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 92nd percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 13,160 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 11.6. This one has done well, scoring higher than 88% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 356,364 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 88% of its contemporaries.
We're also able to compare this research output to 190 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 83% of its contemporaries.